ProPhase Labs Inc. (PRPH)
Company Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.
The company operates in two segments, Diagnostic Services and Consumer Products.
It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services.
It serves national chain drug, internet-based, and various regional retailers.
The company was formerly known as The Quigley Corporation.
ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Country | United States |
IPO Date | Apr 4, 1994 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 96 |
CEO | Ted William Karkus |
Contact Details
Address: 711 Stewart Avenue Garden City, New York United States | |
Website | https://www.prophaselabs.com |
Stock Details
Ticker Symbol | PRPH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000868278 |
CUSIP Number | 74345W108 |
ISIN Number | US74345W1080 |
Employer ID | 23-2577138 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Ted William Karkus | Chairman & Chief Executive Officer |
Stu Hollenshead | Chief Operating Officer |
Jason Karkus | President of Nebula Genomics |
Kamal Obbad | Senior Vice President and Director of Sales & Marketing - Nebula Genomics |
Lance Bisesar | Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 28, 2025 | 8-K | Current Report |
Aug 19, 2025 | DEFA14A | Filing |
Aug 19, 2025 | 8-K | Current Report |
Aug 15, 2025 | DEF 14A | Filing |
Aug 13, 2025 | 10-Q | Quarterly Report |
Aug 13, 2025 | 8-K | Current Report |
Aug 08, 2025 | PRER14A | Filing |
Aug 06, 2025 | 8-K | Current Report |
Aug 05, 2025 | D | Filing |
Jul 29, 2025 | 8-K | Current Report |